Cite

HARVARD Citation

    Linton, K. et al. (n.d.). P650: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BTK DEGRADER, IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL MALIGNANCIES. HemaSphere. pp. 548-549. [Online]. 
  
Back to record